URGN
URGN
NASDAQ · Biotechnology

Urogen Pharma Ltd

$30.22
+3.63 (+13.65%)
As of May 9, 1:38 AM ET ·
Financial Highlights (FY 2026)
Revenue
108.15M
Net Income
-151,209,684
Gross Margin
88.7%
Profit Margin
-139.8%
Rev Growth
+19.5%
D/E Ratio
Revenue & Net Income
Margin Trends
FY 2026 FY 2025 FY 2024 FY 2023
Gross Margin 88.7% 88.7% 31.9% 31.9%
Operating Margin -113.7% -102.4% 7.4% 7.0%
Profit Margin -139.8% -132.8% 5.1% 6.0%
Income Statement
FY 2026 FY 2025 FY 2024 FY 2023
Revenue 108.15M 90.52M 574.93M 620.56M
Gross Profit 95.89M 80.25M 183.53M 198.10M
Operating Income -123,001,069 -92,652,295 42.60M 43.31M
Net Income -151,209,684 -113,900,833 29.33M 36.90M
Gross Margin 88.7% 88.7% 31.9% 31.9%
Operating Margin -113.7% -102.4% 7.4% 7.0%
Profit Margin -139.8% -132.8% 5.1% 6.0%
Rev Growth +19.5% +19.5% -7.8% +0.9%
Balance Sheet
FY 2026 FY 2025 FY 2024 FY 2023
Total Debt 0 0 316.20M 293.87M
Total Equity 463.52M 437.50M
D/E Ratio 0.68 0.67
Cash Flow
FY 2026 FY 2025 FY 2024 FY 2023
EBITDA -141,587,551 -112,577,982 65.79M 68.95M
Free Cash Flow 30.48M 44.33M